For the quarter ended June 2025, BioMarin Pharmaceutical (BMRN) reported revenue of $825.41 million, up 15.9% over the same period last year. EPS came in at $1.44, compared to $0.96 in the year-ago quarter. Here is how BioMarin performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: View all Key Company Metrics for BioMarin here>>> Shares of BioMarin have returned +1.1% over the past month versus the Zacks S&P 500 composite's +0.6% change. ...